Lactobacillus rhamnosus GG 用于 Irritable Bowel Syndrome (IBS)
BSeveral RCTs show improvement in IBS symptoms, particularly bloating and abdominal pain. Effect strongest in IBS-D subtype. Results not uniform across all IBS subtypes.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u002Dgg\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
B
结论
Several RCTs show improvement in IBS symptoms, particularly bloating and abdominal pain. Effect strongest in IBS-D subtype. Results not uniform across all IBS subtypes.
Key Study Findings
Meta-Analysis
Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome.
Dose: None
vs: placebo
Outcome: improvement in key IBS symptoms
效果: None
None
研究人群: patients with IBS from 32 RCTs evaluating 10 probiotic strains
Randomized Controlled Trial
3 weeks
Double-blind
Nutraceuticals and Pain Disorders of the Gut-Brain Interaction in Infants and Children: A Narrative Review …
Dose: None
vs: Placebo
Outcome: Pain outcomes
效果: None
None
研究人群: IBS patients
Systematic Review
n=3
Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic …
Dose: None
vs: None
Outcome: Abdominal pain frequency/intensity, constipation
效果: None
None
研究人群: Children with FAPD or functional constipation
Systematic Review
Probiotics for Irritable Bowel Syndrome: Clinical Data in Children.
Dose: various probiotic strains
vs: placebo
Outcome: IBS symptom improvement in children
效果: LGG showed benefit in some studies
None
研究人群: Children with IBS
Review
Probiotic Bacterial and Fungal Strains: Claims with Evidence.
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: Various populations (probiotic claims review)
Review
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Dose: None
vs: None
Outcome: None
效果: None
None
研究人群: IBD patients
Key Statistics
8
研究数量
1200
受试者
↑
Positive
B
等级
Referenced Papers
Journal of clinical …
2026
Nutrients
2024
5 次引用
Effectiveness of Probiotics in Children With Functional Abdominal Pain Disorders and Functional Constipation: A Systematic Review.
Systematic Review
Journal of clinical …
2018
34 次引用
Digestive diseases (Basel, …
2016
37 次引用
Probiotics for Irritable Bowel Syndrome: Clinical Data in Children.
Systematic Review
Journal of pediatric …
2016
19 次引用
The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts.
Systematic Review
Paediatric drugs
2015
122 次引用
Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children.
Review
Nutrition in clinical …
2015
31 次引用
BMC gastroenterology
2010
91 次引用
Alimentary pharmacology & …
2007
102 次引用
Asia Pacific journal …
2006
45 次引用
Asia Pacific journal …
2006
Alimentary pharmacology & …
2005
398 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 10-20 billion CFU/day
- ibssupport:
- 10 billion CFU/day for 4-8 weeks
- aadprevention:
- 10-20 billion CFU/day (start with antibiotic, continue 7 days after)
上限： Generally well-tolerated up to 40 billion CFU/day in clinical trials
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | 3 weeks | Positive | -- |
| None | -- | Mixed | 3 |
| various probiotic strains | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | 26.0 weeks | Mixed | -- |
最佳服用时间： On an empty stomach or 30 minutes before meals for optimal survival
Safety & Side Effects
已报告的副作用
- ⚠ Mild gas and bloating during initial use (usually resolves in 1-2 weeks)
- ⚠ Rare reports of bacteremia in severely immunocompromised individuals
- ⚠ Occasional loose stools during adjustment period
- ⚠ Very rare: systemic infection in critically ill patients with central venous catheters
已知相互作用
- ● Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
- ● Immunosuppressants (theoretical risk of infection in immunocompromised patients)
- ● Antifungals (no known interaction but may affect gut flora balance)
可耐受最高摄入量： Generally well-tolerated up to 40 billion CFU/day in clinical trials
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does Lactobacillus rhamnosus GG help with Irritable Bowel Syndrome (IBS)?
Based on 8 studies with 1,200 participants, there is moderate evidence from clinical studies that Lactobacillus rhamnosus GG may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is B (Good Evidence).
How much Lactobacillus rhamnosus GG should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 10-20 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus rhamnosus GG?
Reported side effects may include Mild gas and bloating during initial use (usually resolves in 1-2 weeks), Rare reports of bacteremia in severely immunocompromised individuals, Occasional loose stools during adjustment period, Very rare: systemic infection in critically ill patients with central venous catheters. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus rhamnosus GG and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 8 peer-reviewed studies with 1,200 total participants. The overall direction of effect is positive.
Related Evidence
其他成分用于 Irritable Bowel Syndrome (IBS)
Lactobacillus rhamnosus GG 用于其他健康状况
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。